67 TELAPREVIR WITH ADJUSTED DOSE OF RIBAVIRIN IN NAIVE CHC-G1: EFFICACY AND TREATMENT IN CHC IN HEMODIALYSIS POPULATION. TARGET C (RCT)

@article{Basu201367TW,
  title={67 TELAPREVIR WITH ADJUSTED DOSE OF RIBAVIRIN IN NAIVE CHC-G1: EFFICACY AND TREATMENT IN CHC IN HEMODIALYSIS POPULATION. TARGET C (RCT)},
  author={P. Patrick Basu and Ravi Siriki and Niraj James Shah and Sakina Farhat and Kavya Mittimani and Srilakshmi Atluri and M. Rahaman and Robert S Brown},
  journal={Journal of Hepatology},
  year={2013},
  volume={58}
}
PWE-126 Table AVR 1 week VRVR 2 weeks RVR 4 weeks EVR 12 weeks MTVR 18 weeks ETVR 24weeks SVR 48 weeks SVR 60 weeks SVR 72 weeks Group A n=18 SVR 24 weeks VL 820k G1a 8 G1b 7 Il28b CC 5 TT 5 CT 8 10/18(55%) 4/8(50% 6/7(87%) 5/10(50) 1/10(10) 4/10(40) 12/18(67%) 
Sofosbuvir and simeprevir in hepatitis C genotype 1‐patients with end‐stage renal disease on haemodialysis or GFR <30 ml/min
  • H. Nazario, M. Ndungu, A. Modi
  • Medicine
  • Liver international : official journal of the International Association for the Study of the Liver
  • 2016
Treating chronic hepatitis C (CHC) in patients with end‐stage renal disease (ESRD) has suboptimal tolerability and cure rates. Safety and efficacy of sofosbuvir plus simeprevir regimen inExpand
Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa
TLDR
Because the SVR rates in Asian HCV patients receiving PEG-IFN α plus ribavirin therapy are high, health care providers should judiciously determine the clinical usefulness of these novel agents on the basis of treatment duration, anticipated viral responses, patient tolerance, financial burdens, and drug accessibility. Expand
Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity
TLDR
The development of direct-acting antiviral agents has revolutionized the treatment of chronic hepatitis C; interferon-free regimens, likely consisting of several oral agents, represent the future of HCV therapy. Expand
Treatment decisions and contemporary versus pending treatments for hepatitis C
TLDR
A disparity exists, as response rates are reduced in patients with cirrhosis and the risks of adverse events are increased, so patients with mild disease could consider deferring treatment. Expand
An update on the treatment of genotype-1 chronic hepatitis C infection: lessons from recent clinical trials
TLDR
The development of pan-genotypic DAAs (NIs or NS5A.I) allows new combinations with or without PR that increase the rate of sustained virological response (SVR) for all patients, even for those with cirrhosis and independently of the genotype. Expand
Ribavirin with interferon for hepatitis C in dialysis patients: efficacious and safe in the right patients in good hands
TLDR
It has not been shown, though it is possible, that HCV clearance might ameliorate the adverse impact of infection on cardiovascular complications before and after transplantation, but it has been shown that the absolute risk for cardiovascular mortality is much greater than risk of HCV-related mortality in patients with RRT and KT. Expand
New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment
TLDR
Information is gathered on dosage adjustment for renal function in patients receiving very new drugs for hepatitis C, and information, although scarce, is gathered to propose guidelines for using these drugs in patients with chronic kidney disease. Expand
Management of patients with hepatitis C infection and renal disease.
TLDR
This review will be focused on the evaluations, available pharmacologic data, and management of HCV in patients with severe renal impairment, patients who underwent KT, and those who suffered from HCV-related renal disease, according to the available treatment options, including DAA. Expand
Interventions for dialysis patients with hepatitis C virus (HCV) infection.
TLDR
The aims were to look at the benefits and harms of various interventions for HCV infection in CKD patients on HD or peritoneal dialysis, specifically on mortality, disease relapse, response to treatment, treatment discontinuation, time to recovery, quality of life, cost effectiveness, adverse effects, and other outcomes. Expand
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
TLDR
These EASL CPGs on the management of HCV infection have been updated to include guidance on the use of these two protease inhibitors, and will be updated regularly based on approval of additional new therapies and clinical experience with them. Expand
...
1
2
...